The PROSPET-BX trial compared [68Ga]PSMA-11 PET/CT (PSMA-PET) with multiparametric MRI (mpMRI) in parallel in men with suspicion of prostate cancer (PCa) after at least one previously negative biopsy (ClinicalTrials. gov: NCT05297162; GR-2018-12366240). In this study, we performed the cost analysis of the two imaging modalities with respect to the detection of clinically significant PCa (csPCa).
We analyzed the data from patients enrolled in the trial who met the inclusion criteria. For the cost analysis, we identified six competing triage strategies, each defined as a binary decision rule for referral to prostate biopsy: (1) biopsy-all; (2) elevated PSA-density (PSAD; biopsy if PSAD > 0.15 ng/mL/cc; (3) mpMRI positive (PIRADS 3-5); (4) PSMA-PET positive (PRIMARY 3-5); (5) mpMRI or PSMA-PET positive; (6) PSAD and mpMRI. For each strategy, we yielded sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for csPCa. Direct hospital costs were modeled from a provider perspective, incorporating testing and procedural costs. Unit costs (in EUR) were sourced from our institutional accounting records. Pairwise cost-effectiveness comparisons were performed using incremental cost-effectiveness ratio (ICER) and incremental net benefit (INB).
Among the six triage strategies evaluated, the "biopsy-all" approach achieved perfect sensitivity, whereas the PSAD + mpMRI pathway was the most parsimonious strategy but missed 14 csPCa cases (53.8%). The combined "mpMRI or PSMA-PET" strategy maximized detection (22 cPCa, missing only 4) at an intermediate cost (EUR 81.991 total; EUR 3.727 per csPCa). The pairwise comparison of each strategy with mpMRI alone showed for the mpMRI or PSMA-PET pathway a low ICER (~EUR 2.900/extra csPCa), with consistently positive and increasing INB across higher WTP (willingness-to-pay). Therefore, this combination provided the most favorable cost-effectiveness profile, balancing detection, efficiency, and cost.
To the best of our knowledge, this is the first cost analysis study to compare different strategies incorporating PSMA-PET in the re-biopsy setting, demonstrating that the combined "mpMRI or PSMA-PET" pathway is the most cost-effective diagnostic pathway for csPCa detection.
Cancers. 2026 Mar 02*** epublish ***
Egesta Lopci, Cesare Saitta, Alberto Saita, Elena Vanni, Alessandro Santandrea, Luca Disconzi, Vittorio Fasulo, Nicolò Buffi, Massimo Lazzeri, Giovanni Lughezzani
Nuclear-Medicine Unit, IRCCS-Humanitas Research Hospital, 20089 Rozzano, MI, Italy., Urology Unit, IRCCS-Humanitas Research Hospital, 20089 Rozzano, MI, Italy., Business Operating Office, IRCCS-Humanitas Research Hospital, 20089 Rozzano, MI, Italy., Radiology Department, IRCCS-Humanitas Research Hospital, 20089 Rozzano, MI, Italy.